Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• "Moderate Buy" consensus from nine analysts (1 sell, 2 hold, 4 buy, 2 strong buy) with an average 12‑month price target of $12.33.
• Haleon declared a dividend of $0.1307 per share, payable on May 14 with a record (and ex‑dividend) date of April 10.
• Shares opened at $9.26, trading below the 50‑day moving average ($10.05) and near the 200‑day ($9.97); 12‑month range is $8.71–$11.42, market cap ≈ $41.2B and P/E ~23.7.

Shares of Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $12.3250.

Several research firms recently weighed in on HLN. Jefferies Financial Group restated a "buy" rating on shares of Haleon in a report on Tuesday, January 20th. Wall Street Zen upgraded Haleon from a "hold" rating to a "buy" rating in a report on Saturday, March 21st. Weiss Ratings restated a "hold (c)" rating on shares of Haleon in a report on Thursday, January 22nd. HSBC upgraded Haleon from a "hold" rating to a "strong-buy" rating in a report on Wednesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Haleon in a report on Thursday.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HLN. Brighton Jones LLC acquired a new position in shares of Haleon during the fourth quarter worth approximately $187,000. AQR Capital Management LLC lifted its holdings in shares of Haleon by 22.5% during the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company's stock worth $991,000 after buying an additional 17,720 shares during the last quarter. Focus Partners Wealth lifted its holdings in shares of Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company's stock worth $752,000 after buying an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company's stock worth $50,000 after buying an additional 1,203 shares during the last quarter. Finally, CW Advisors LLC lifted its holdings in shares of Haleon by 11.6% during the second quarter. CW Advisors LLC now owns 25,075 shares of the company's stock worth $260,000 after buying an additional 2,601 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Down 0.5%

HLN opened at $9.26 on Friday. The business has a 50 day moving average price of $10.05 and a 200 day moving average price of $9.97. Haleon has a twelve month low of $8.71 and a twelve month high of $11.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. The firm has a market cap of $41.22 billion, a P/E ratio of 23.73, a price-to-earnings-growth ratio of 1.97 and a beta of 0.26.

Haleon (NYSE:HLN - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The company had revenue of $3.65 billion during the quarter. Research analysts forecast that Haleon will post 0.56 EPS for the current year.

Haleon Dividend Announcement

The firm also recently declared a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be issued a dividend of $0.1307 per share. The ex-dividend date is Friday, April 10th. This represents a dividend yield of 266.0%. Haleon's payout ratio is 64.10%.

About Haleon

Haleon plc NYSE: HLN is a global consumer healthcare company formed through the separation of a large pharmaceutical group's consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.